Literature DB >> 27831656

Why is it so difficult to integrate ethics in Health Technology Assessment (HTA)? The epistemological viewpoint.

P Refolo1, D Sacchini, L Brereton, A Gerhardus, B Hofmann, K B Lysdahl, K Mozygemba, W Oortwijn, M Tummers, G J van der Wilt, P Wahlster, A G Spagnolo.   

Abstract

Ethics has been identified as a key element in Health Technology Assessment (HTA) since its conception. However, ethical issues are still not frequently addressed explicitly in HTA. Several valuable reasons have been identified. The basis of the article is the claim that ethics is often not part of HTA for "epistemological reasons". Hence, the main aim of the contribution is to explore in more details and emphasize them by using the fact/value dichotomy. Our conclusion is that current HTA configuration is predominantly based on the comparison among objective and empirically testable "facts", whilst ethics is not empirically testable. In this sense, there is a sort of "epistemological gap", which can explain why it is so difficult to integrate ethics in HTA. We suggest that the epistemological differences among the various domains of HTA are addressed more explicitly.

Mesh:

Year:  2016        PMID: 27831656

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

2.  Evaluation of Ethical Analyses in Seven Reports from the European Network for Health Technology Assessment.

Authors:  Perihan Elif Ekmekci; Müberra Devrim Güner
Journal:  Int J Technol Assess Health Care       Date:  2019-07-16       Impact factor: 2.188

Review 3.  Prioritization of COVID-19 vaccination. The added value of the "VALIDATE" approach.

Authors:  Pietro Refolo; Bart Bloemen; Barbara Corsano; John Grin; Iñaki Gutierrez-Ibarluzea; Bjørn Hofmann; Wija Oortwijn; Laura Sampietro-Colom; Lars Sandman; Gert Jan van der Wilt; Dario Sacchini
Journal:  Health Policy       Date:  2022-05-20       Impact factor: 3.255

4.  Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.

Authors:  Elisabete Gonçalves
Journal:  Eur J Health Econ       Date:  2020-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.